In a significant shift in drug policy, President Trump has signed an executive order reclassifying marijuana as a less dangerous drug. This move is aimed at expanding access to cannabis for research and medical purposes, following extensive lobbying from the cannabis industry. The order is expected to expedite the reclassification process, potentially moving marijuana to Schedule III, which could lower taxes on cannabis businesses and pave the way for broader access. However, the plan has faced criticism from some GOP senators who warn it may adversely affect the economy. Amid these developments, cannabis stocks have seen fluctuating fortunes, with some companies experiencing gains while others faced declines due to uncertainties surrounding the changes. The reclassification is anticipated to have far-reaching implications for federal cannabis laws and the ongoing discourse surrounding marijuana legalization in various states.